Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $2.64B
• Dividend Yield: N/A
• Average Volume (3M): 7.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.36
• Revenue Growth: 14.99%
• EPS Growth: 14.42%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 107,346,886
• 10 Day Avg. Volume: 7,455,632
• 30 Day Avg. Volume: 7,110,190
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.23
• Enterprise Value/Revenue: 11.65
• Enterprise Value/Gross Profit: 12.91
• Enterprise Value/Ebitda: -1.23
• 1Y Price Target: $31.81
• Price Target Upside: 29.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 62 Neutral
• Price Target: $29.00 ▲(17.98% Upside)

Intellia Therapeutics' overall stock score is driven by strong technical indicators and positive earnings call sentiment, reflecting progress in clinical trials and financial stability. However, financial performance remains a concern due to ongoing losses and negative cash flows, typical of a biotech firm in development. Valuation is challenging with a negative P/E ratio, but the company's strategic focus on growth and innovation offers potential long-term rewards.

Positive Factors

Clinical Trial Progress

Accelerated enrollment in Phase III studies indicates strong demand and interest, potentially leading to faster time-to-market for new therapies, enhancing the company's competitive position.

Cash Position

A robust cash position provides financial stability and supports ongoing R&D activities, ensuring the company can continue its strategic initiatives without immediate financial constraints.

Positive Clinical Data

Positive clinical data strengthens the company's pipeline credibility and enhances the potential for successful commercialization of its therapies, supporting long-term growth prospects.

Negative Factors

Revenue Decline

A significant decline in revenue highlights challenges in generating consistent income, which may impact the company's ability to sustain operations without external funding.

High Operating Costs

High operational costs leading to substantial losses can strain financial resources, necessitating careful management to avoid jeopardizing long-term financial health.

Adverse Events in Trials

Adverse events in clinical trials, even if mild, can pose risks to patient safety perceptions and regulatory approvals, potentially delaying product development timelines.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc. (NTLA) is a biotechnology company focused on developing transformative therapies using its proprietary CRISPR/Cas9 gene-editing technology. The company operates in the healthcare sector, primarily in the field of genetic medicine, targeting a range of diseases including genetic disorders, cancers, and other serious conditions. Intellia's core products and services revolve around its innovative gene-editing platform, which aims to provide one-time curative treatments by directly addressing the root causes of diseases at the genetic level.

How the Company Makes Money

Intellia Therapeutics generates revenue through several key streams. Primarily, the company earns money by developing and advancing its therapeutic candidates through clinical trials and subsequently partnering with larger pharmaceutical companies for commercialization. These partnerships often involve upfront payments, research funding, and milestone payments based on the achievement of specific development goals. Additionally, Intellia may receive royalties on sales of products that emerge from these collaborations. The company also benefits from government grants and research funding aimed at advancing gene-editing technologies. Significant partnerships with major firms in the pharmaceutical industry further contribute to Intellia's revenue model, providing financial support and shared resources for the development of its therapies.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is in a typical growth and development phase for a biotech company, characterized by high R&D expenses leading to net losses and negative cash flows. While the company maintains a strong cash position, its revenue has dwindled, and its balance sheet reflects declining shareholder equity. The financials suggest the firm is investing heavily in its pipeline, which is common in biotechnology, but it faces significant risks related to its future revenue generation and profitability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.86M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	47.68M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-501.87M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-480.19M	-519.02M	-481.19M	-474.19M	-267.89M	-134.23M
Balance Sheet
Total Assets	898.89M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	459.65M	601.51M	912.22M	1.19B	748.69M	597.37M
Total Debt	102.59M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	183.64M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	715.25M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-421.82M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-418.58M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	345.09M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	99.16M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 24.58 is above the 20-day moving average (MA) of 22.69, above the 50-day MA of 16.52, and above the 200-day MA of 11.35, indicating a bullish trend. The MACD of 2.87 indicates Positive momentum. The RSI at 64.63 is Neutral, neither overbought nor oversold. The STOCH value of 61.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	62 Neutral	$2.64B	-5.52	-56.95%	―	14.99%	14.42%
VIR	55 Neutral	$871.01M	―	-46.22%	―	-75.91%	-12.11%
XNCR	54 Neutral	$947.88M	-5.10	-29.22%	―	-2.07%	22.52%
ARVN	52 Neutral	$683.52M	-1.77	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRIX	50 Neutral	$801.13M	―	-65.35%	―	48.32%	-1.91%
RCKT	40 Underperform	$410.03M	-1.49	-69.65%	―	―	10.36%

Intellia Therapeutics Corporate Events

Intellia Therapeutics Announces Positive Phase 1 Trial Results

On September 25, 2025, Intellia Therapeutics announced positive longer-term data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy. The trial showed deep, durable TTR reductions and favorable safety data, with most patients experiencing stability or improvement in clinical measures. The company is advancing its Phase 3 MAGNITUDE-2 trial, with completion of enrollment expected in the first half of 2026, and plans to submit a biologics license application by 2028.

The most recent analyst rating on (NTLA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?

Study Overview: Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for individuals with hemophilia B, a condition caused by a genetic mutation in the coagulation Factor 9 gene. The primary goal is to determine a safe and well-tolerated dose of the therapy, with secondary objectives including the assessment of drug presence in the blood, antibody formation, and the impact on quality of life and joint health.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for hemophilia B, focusing on finding a safe and well-tolerated dose while assessing various health impacts on participants.

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN

Regeneron Pharmaceuticals and Intellia Therapeutics have launched a Phase 3 clinical study titled ‘MAGNITUDE-2’ to assess the efficacy and safety of NTLA-2001 in treating hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This study is crucial as it explores a potential breakthrough treatment for a debilitating genetic disorder.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer?

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for individuals with hemophilia B, focusing on finding a safe dose and assessing the therapy’s impact on quality of life, joint health, and the need for factor replacement therapy.

Intellia Therapeutics’ Earnings Call Highlights Progress and Challenges

Intellia Therapeutics Inc. recently held its earnings call, reflecting a generally positive sentiment regarding its clinical programs, financial stability, and operational progress. While the company is making significant strides, it also faces challenges such as the impending retirement of its Chief Medical Officer and increasing competitive pressures in the market.

Intellia Therapeutics Reports Q2 2025 Progress and Financials

Intellia Therapeutics, Inc. is a clinical-stage gene editing company leveraging CRISPR-based therapies to develop innovative treatments for severe diseases. In its second quarter of 2025 financial results, Intellia reported significant progress in its clinical trials, notably in the Phase 3 MAGNITUDE trial for ATTR amyloidosis and the HAELO study for hereditary angioedema. The company ended the quarter with $630.5 million in cash, expecting to fund operations into 2027.

Intellia Therapeutics Announces Executive Retirement

On August 7, 2025, Intellia Therapeutics announced the upcoming retirement of Dr. David Lebwohl, the company’s Executive Vice President and Chief Medical Officer, effective August 7, 2026. The company also reported strong progress in its clinical trials, including the Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy and the Phase 3 HAELO study for hereditary angioedema, both of which are ahead of schedule. The company ended the second quarter with $630.5 million in cash and is expected to fund operations into the first half of 2027, indicating a robust financial position to support its ongoing and future projects.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a Phase 3 clinical study titled ‘MAGNITUDE-2’ to evaluate the efficacy and safety of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This study aims to assess the impact of a single dose of NTLA-2001 compared to a placebo, highlighting its potential significance in treating this rare genetic disorder.

Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM

The recent clinical study titled ‘MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)’ aims to evaluate the efficacy and safety of NTLA-2001. This study is significant as it targets ATTR-CM, a condition with limited treatment options, potentially offering a new therapeutic pathway.

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B

Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for Hemophilia B, focusing on finding a safe dose and assessing the therapy’s impact on quality of life and joint health.